KR102748047B1 - Egfr 이량체 붕괴제 및 이의 용도 - Google Patents

Egfr 이량체 붕괴제 및 이의 용도 Download PDF

Info

Publication number
KR102748047B1
KR102748047B1 KR1020207027147A KR20207027147A KR102748047B1 KR 102748047 B1 KR102748047 B1 KR 102748047B1 KR 1020207027147 A KR1020207027147 A KR 1020207027147A KR 20207027147 A KR20207027147 A KR 20207027147A KR 102748047 B1 KR102748047 B1 KR 102748047B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
reaction mixture
egfr
triazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207027147A
Other languages
English (en)
Korean (ko)
Other versions
KR20200124709A (ko
Inventor
무케시 케이. 냐티
티오도르 에스. 로렌스
크리스토퍼 와이트헤드
제이슨 크리스토퍼 레시
브레넌 테일러 워치
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시간
Publication of KR20200124709A publication Critical patent/KR20200124709A/ko
Application granted granted Critical
Publication of KR102748047B1 publication Critical patent/KR102748047B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207027147A 2018-02-23 2019-02-25 Egfr 이량체 붕괴제 및 이의 용도 Active KR102748047B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634452P 2018-02-23 2018-02-23
US62/634,452 2018-02-23
PCT/US2019/019391 WO2019165358A1 (en) 2018-02-23 2019-02-25 Egfr dimer disruptors and use of the same

Publications (2)

Publication Number Publication Date
KR20200124709A KR20200124709A (ko) 2020-11-03
KR102748047B1 true KR102748047B1 (ko) 2024-12-27

Family

ID=67688515

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027147A Active KR102748047B1 (ko) 2018-02-23 2019-02-25 Egfr 이량체 붕괴제 및 이의 용도

Country Status (11)

Country Link
US (2) US11358965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755323A4 (cg-RX-API-DMAC7.html)
JP (2) JP7497046B2 (cg-RX-API-DMAC7.html)
KR (1) KR102748047B1 (cg-RX-API-DMAC7.html)
CN (1) CN111886009A (cg-RX-API-DMAC7.html)
AU (1) AU2019223168B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017184A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091834A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092000A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008767A (cg-RX-API-DMAC7.html)
WO (1) WO2019165358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019223168B2 (en) 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same
CN119454706A (zh) * 2019-08-22 2025-02-18 密歇根大学董事会 治疗kras相关癌症的方法
IL296091A (en) * 2020-03-05 2022-11-01 Univ Michigan Regents Inhibitors of braf, kras, egfr and other targets and their uses
CN115397413A (zh) * 2020-03-05 2022-11-25 密歇根大学董事会 Egfr、kras、braf和其他靶标的抑制剂及其用途
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022077154A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Michigan Synthesis of egfr modulators
CN116997551A (zh) * 2020-10-12 2023-11-03 密歇根大学董事会 Egfr调节剂的合成
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
KR20240016250A (ko) * 2021-04-02 2024-02-06 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료를 위한 병용요법
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
EP4724150A1 (en) 2023-06-08 2026-04-15 Antares Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
EP3096761A1 (en) * 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2019223168B2 (en) * 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof

Also Published As

Publication number Publication date
BR112020017184A2 (pt) 2020-12-22
EP3755323A4 (en) 2021-11-24
US11999731B2 (en) 2024-06-04
MX2020008767A (es) 2021-01-08
AU2019223168A1 (en) 2020-09-10
EA202092000A1 (ru) 2020-12-09
CN111886009A (zh) 2020-11-03
AU2019223168B2 (en) 2024-09-12
EP3755323A1 (en) 2020-12-30
WO2019165358A1 (en) 2019-08-29
CA3091834A1 (en) 2019-08-29
US20220340572A1 (en) 2022-10-27
KR20200124709A (ko) 2020-11-03
US20200377503A1 (en) 2020-12-03
JP2024056735A (ja) 2024-04-23
JP2021514001A (ja) 2021-06-03
JP7497046B2 (ja) 2024-06-10
US11358965B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
JP7497046B2 (ja) Egfr二量体撹乱剤およびその使用
JP7241810B2 (ja) Hpk1阻害剤およびそれを用いる方法
US10435388B2 (en) Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
JP2023515691A (ja) Egfr、kras、braf、および他の標的の阻害剤およびそれらの使用
JP5770281B2 (ja) c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
US6608048B2 (en) Tricyclic protein kinase inhibitors
TWI532743B (zh) As a novel fused ring heterocyclic derivative of c-Met inhibitors
KR20220050143A (ko) Kras-관련 암 치료 방법
ES2610226T3 (es) Compuestos de 6-amino-piridazin-3-il-carboxamida sustituidos como moduladores de proteínas cinasas
KR20220150358A (ko) Egfr, kras, braf 및 다른 표적의 저해제 및 이들의 용도
KR20200028966A (ko) Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
CN107922403A (zh) 作为胆碱能毒蕈碱m1受体的调节剂的2,3‑二氢‑4h‑1,3‑苯并噁嗪‑4‑酮衍生物
EA042609B1 (ru) Ингибиторы димеризации egfr и их использование
HK40034660A (en) Egfr dimer disruptors and use of the same
EP4741375A1 (en) Sulfonylurea derivatives and their use for the treatment of cancer
WO2026099404A1 (en) Sulfonylurea derivatives and their use for the treatment of cancer
HK40057478B (en) Hpk1 inhibitors and methods of using same
TW202214585A (zh) 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法
HK1221720A1 (zh) 喹唑啉衍生物及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200921

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240217

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240925

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241224

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration